215 related articles for article (PubMed ID: 37705104)
21. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.
Xia D; Lianoglou S; Sandmann T; Calvert M; Suh JH; Thomsen E; Dugas J; Pizzo ME; DeVos SL; Earr TK; Lin CC; Davis S; Ha C; Leung AW; Nguyen H; Chau R; Yulyaningsih E; Lopez I; Solanoy H; Masoud ST; Liang CC; Lin K; Astarita G; Khoury N; Zuchero JY; Thorne RG; Shen K; Miller S; Palop JJ; Garceau D; Sasner M; Whitesell JD; Harris JA; Hummel S; Gnörich J; Wind K; Kunze L; Zatcepin A; Brendel M; Willem M; Haass C; Barnett D; Zimmer TS; Orr AG; Scearce-Levie K; Lewcock JW; Di Paolo G; Sanchez PE
Mol Neurodegener; 2022 Jun; 17(1):41. PubMed ID: 35690868
[TBL] [Abstract][Full Text] [Related]
22. Omega-3 polyunsaturated fatty acids promote brain-to-blood clearance of β-Amyloid in a mouse model with Alzheimer's disease.
Yan L; Xie Y; Satyanarayanan SK; Zeng H; Liu Q; Huang M; Ma Y; Wan JB; Yao X; Su KP; Su H
Brain Behav Immun; 2020 Mar; 85():35-45. PubMed ID: 31132459
[TBL] [Abstract][Full Text] [Related]
23. Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model.
Huynh TV; Wang C; Tran AC; Tabor GT; Mahan TE; Francis CM; Finn MB; Spellman R; Manis M; Tanzi RE; Ulrich JD; Holtzman DM
Mol Neurodegener; 2019 Oct; 14(1):37. PubMed ID: 31623648
[TBL] [Abstract][Full Text] [Related]
24. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
Kurz C; Walker L; Rauchmann BS; Perneczky R
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E genotype-dependent accumulation of amyloid β in APP-knock-in mouse model of Alzheimer's disease.
Takebayashi Y; Yamazaki Y; Yamada H; Yazawa K; Nakamori M; Kurashige T; Morino H; Takahashi T; Sotomaru Y; Maruyama H
Biochem Biophys Res Commun; 2023 Nov; 683():149106. PubMed ID: 37857162
[TBL] [Abstract][Full Text] [Related]
26. Proteomics Time-Course Study of App Knock-In Mice Reveals Novel Presymptomatic Aβ42-Induced Pathways to Alzheimer's Disease Pathology.
Schedin-Weiss S; Nilsson P; Sandebring-Matton A; Axenhus M; Sekiguchi M; Saito T; Winblad B; Saido T; Tjernberg LO
J Alzheimers Dis; 2020; 75(1):321-335. PubMed ID: 32280097
[TBL] [Abstract][Full Text] [Related]
27. TNF-α and IL-1β Modulate Blood-Brain Barrier Permeability and Decrease Amyloid-β Peptide Efflux in a Human Blood-Brain Barrier Model.
Versele R; Sevin E; Gosselet F; Fenart L; Candela P
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142143
[TBL] [Abstract][Full Text] [Related]
28. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
29. Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.
Kook SY; Hong HS; Moon M; Ha CM; Chang S; Mook-Jung I
J Neurosci; 2012 Jun; 32(26):8845-54. PubMed ID: 22745485
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium.
Wang Z; Sharda N; Omtri RS; Li L; Kandimalla KK
Mol Pharmacol; 2023 Nov; 104(5):203-213. PubMed ID: 37541759
[TBL] [Abstract][Full Text] [Related]
31. Network-guided analysis of hippocampal proteome identifies novel proteins that colocalize with Aβ in a mice model of early-stage Alzheimer's disease.
Aladeokin AC; Akiyama T; Kimura A; Kimura Y; Takahashi-Jitsuki A; Nakamura H; Makihara H; Masukawa D; Nakabayashi J; Hirano H; Nakamura F; Saito T; Saido T; Goshima Y
Neurobiol Dis; 2019 Dec; 132():104603. PubMed ID: 31494281
[TBL] [Abstract][Full Text] [Related]
32. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
33. Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Sarkar S
Neuroscience; 2020 Aug; 440():48-55. PubMed ID: 32450297
[TBL] [Abstract][Full Text] [Related]
34. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
35. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
[TBL] [Abstract][Full Text] [Related]
36. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease.
Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J
Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603
[TBL] [Abstract][Full Text] [Related]
37. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
Do TM; Alata W; Dodacki A; Traversy MT; Chacun H; Pradier L; Scherrmann JM; Farinotti R; Calon F; Bourasset F
Neuropharmacology; 2014 Jun; 81():311-7. PubMed ID: 24631967
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model.
Blacher E; Dadali T; Bespalko A; Haupenthal VJ; Grimm MO; Hartmann T; Lund FE; Stein R; Levy A
Ann Neurol; 2015 Jul; 78(1):88-103. PubMed ID: 25893674
[TBL] [Abstract][Full Text] [Related]
39. Alzheimer's disease amyloid-β pathology in the lens of the eye.
Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
[TBL] [Abstract][Full Text] [Related]
40. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease.
Rofo F; Metzendorf NG; Saubi C; Suominen L; Godec A; Sehlin D; Syvänen S; Hultqvist G
Alzheimers Res Ther; 2022 Dec; 14(1):180. PubMed ID: 36471433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
